morrocan.png
DSCF9639-2.jpg
morrocan.png

Improving patient outcomes today. Transforming cancer care tomorrow.


Harnessing 3D organoid technology and AI for more effective treatment options and accelerated drug development.

SCROLL DOWN

Improving patient outcomes today. Transforming cancer care tomorrow.


Harnessing 3D organoid technology and AI for more effective treatment options and accelerated drug development.

Our Solution


Beyond DNA Sequencing

SEngine Precision Medicine empowers patients and oncologists with more informed treatment options. SEngine's high-throughput technology simultaneously tests more than 100 cancer drugs against a patient's unique tumor organoid outside the body. The results decode the most effective and least toxic treatment options that DNA sequencing alone cannot reveal. The AI-optimized platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs.

DSCF9639-2.jpg

Available Now


Serving Patients, Research Partners and Pharmaceuticals

Available Now


Serving Patients, Research Partners and Pharmaceuticals

The PARIS® Test is the antidote for today's failing standard of care. DNA sequencing alone predicts effective treatment an estimated 7% of the time. The PARIS Test delivers effective treatment options for solid tumors up to 80% of the time, based on recent testing. As a CLIA-certified lab, SEngine is the only lab which provides actionable reports directly to oncologists today.